期刊
NMR IN BIOMEDICINE
卷 22, 期 1, 页码 65-76出版社
WILEY
DOI: 10.1002/nbm.1217
关键词
breast; cancer; MRS; quantification; choline; high-field MR
资金
- NIH [CA120509, CA092004, RR008079, RR00400]
- Tickle Family Land Grant Endowment in Breast Cancer Research
- PHS Cancer Center [P30 CA77398]
- Lillian Quist-Joyce Henline Chair in Biomedical Research
- NATIONAL CANCER INSTITUTE [R01CA077398, R01CA120509, R01CA092004] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008079, M01RR000400] Funding Source: NIH RePORTER
In vivo H-1 MRS is rapidly developing as a clinical tool for diagnosing and characterizing breast cancers. Many in vivo and in vitro experiments have demonstrated that alterations in concentrations of choline-containing metabolites are associated with malignant transformation. In recent years, considerable efforts have been made to evaluate the role of H-1 MRS measurements of total choline-containing compounds in the management of patients with breast cancer. Current technological developments, including the use of high-field MR scanners and quantitative spectroscopic analysis methods, promise to increase the sensitivity and accuracy of breast MRS. This article reviews the literature describing in vivo MRS in breast cancer, with an emphasis on the development of high-field MR scanning and quantitative methods. Potential applications of these technologies for diagnosing suspicious lesions and monitoring response to chemotherapy are discussed. Copyright (C) 2007 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据